European Journal of Echocardiography Advance Access originally published online on May 13, 2008
European Journal of Echocardiography 2008 9(6):809-815; doi:10.1093/ejechocard/jen155
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study)
1 Institute of Medicine, University of Bergen, N-5021 Bergen, Norway
2 Department of Heart Disease, Haukeland University Hospital, N-5021 Bergen, Norway
3 Department of Clinical and Experimental Medicine, Federico II University Hospital, Via S. Pansini 5, 80131 Naples, Italy
4 Department of Cardiology, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark
5 Department of Medicine, Sahlgrenska University Hospital/Östra, 416 85 Göteborg, Sweden
6 Division of Cardiology, Weill Medical College of Cornell University, 525 East 68th Street, Box 22, New York, NY 10021, USA
Received 23 October 2007; accepted after revision 12 April 2008; online publish-ahead-of-print 13 May 2008.
* Corresponding author. Tel: +47 55972220; fax: +47 55975150. E-mail address: gerdtsev{at}online.no
| Abstract |
|---|
Aims: Less is known about the relation between in-treatment left ventricular (LV) geometry and risk of cardiovascular events. We assessed LV geometric patterns on baseline and annual echocardiograms as time-varying predictors of the primary composite endpoint (cardiovascular death, stroke, and myocardial infarction) in 937 hypertensive patients with LV hypertrophy during 4.8 years losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) echocardiography substudy.
Methods and results: LV geometry was determined from LV mass/body surface area and relative wall thickness in combination. At end of the study, 52% of patients with initial LV hypertrophy had normal geometry (P < 0.001). In particular, concentric remodelling was reduced by 82% and concentric LV hypertrophy by 84%. Development of LV hypertrophy was seen in <5%. In Cox regression analyses including LV geometric patterns as time-varying variables and adjusting for treatment, Framingham risk score, race, and time-varying systolic blood pressure, the patterns independently predicted higher risk of primary composite endpoints [HR 2.99 (1.16–7.71) for concentric remodelling, HR 1.79 (1.17–2.73) for eccentric hypertrophy, and HR 2.71 (1.13–6.45) for concentric hypertrophy; all P < 0.05].
Conclusion: In hypertensive patients with ECG LV hypertrophy, in-treatment LV geometry by echocardiography adds information on risk of cardiovascular events.
Keywords: Hypertension; Left ventricular geometry; Left ventricular hypertrophy; Losartan; Atenolol
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. A. Chirinos, P. Segers, A. K. Gupta, A. Swillens, E. R. Rietzschel, M. L. De Buyzere, J. N. Kirkpatrick, T. C. Gillebert, Y. Wang, M. G. Keane, et al. Time-Varying Myocardial Stress and Systolic Pressure-Stress Relationship: Role in Myocardial-Arterial Coupling in Hypertension Circulation, June 2, 2009; 119(21): 2798 - 2807. [Abstract] [Full Text] [PDF] |
||||
